1naresh
Array
(
    [urn:ac.highwire.org:guest:identity] => Array
        (
            [runtime-id] => urn:ac.highwire.org:guest:identity
            [type] => guest
            [service-id] => ajnr-ac.highwire.org
            [access-type] => Controlled
            [privilege] => Array
                (
                    [urn:ac.highwire.org:guest:privilege] => Array
                        (
                            [runtime-id] => urn:ac.highwire.org:guest:privilege
                            [type] => privilege-set
                            [privilege-set] => GUEST
                        )
                )
            [credentials] => Array
                (
                    [method] => guest
                )
        )
)
1nareshArray
(
    [urn:ac.highwire.org:guest:identity] => Array
        (
            [runtime-id] => urn:ac.highwire.org:guest:identity
            [type] => guest
            [service-id] => ajnr-ac.highwire.org
            [access-type] => Controlled
            [privilege] => Array
                (
                    [urn:ac.highwire.org:guest:privilege] => Array
                        (
                            [runtime-id] => urn:ac.highwire.org:guest:privilege
                            [type] => privilege-set
                            [privilege-set] => GUEST
                        )
                )
            [credentials] => Array
                (
                    [method] => guest
                )
        )
)
Table 1: Baseline characteristics
Parameter (n = 25) Age (mean) (yr) 77.3 ± 10.3 Sex (male) (%) 10 (40) Occluded vessel     Proximal ICA (No.) (%) 1 (4)     Carotid terminus (No.) (%) 11 (44)     M1 (No.) (%) 11 (44)     M2 (No.) (%) 2 (8) IV thrombolysis (No.) (%) 15 (60) Transfer patientsa     Drip and ship (No.) (%) 14 (56)     Ship and drip (No.) (%) 1 (4)     Just ship (No.) (%) 10 (40) General anesthesia at the time of FDCT (No.) (%) 3 (12) Arterial hypertension (No.) (%) 19 (76) Hyperlipoproteinemia (No.) (%) 11 (44) Diabetes mellitus (No.) (%) 9 (36) Atrial fibrillation (No.) (%) 8 (32) Coronary artery disease (No.) (%) 9 (36) Chronic kidney failure (No.) (%) 7 (28) NIHSS score on admission (median) (IQR) 17 (14–19) mRS score on admission (median) (IQR) 5 (4–5) Successful reperfusion (No.) (%) 22 (88) Symptom-to-groin time (mean) (min) 249.3 ± 57.1 Symptom-to-reperfusion time (n = 22) (mean) (min) 294.6 ± 66.3 Door-to-groin time (mean) (min) 25.2 ± 8.9 Door-to-reperfusion time (n = 22) (mean) (min) 77.3 ± 30 Symptom-to-MDCT time (mean) (min) 99.4 ± 52.6 Symptom-to-FDCT time (mean) (min) 234.9 ± 55.2 MDCT-to-FDCT time (mean) (min) 143.6 ± 49.5 MDCT ASPECTS (median) (IQR) 7 (5.5–9) FDCT ASPECTS (median) (IQR) 7 (4.25–8) 
↵a Drip and ship: transfer patients with IV thrombolysis started in a peripheral stroke center; ship and drip: transfer patients with IV thrombolysis started in our tertiary stroke center; just ship: transfer patients without IV thrombolysis.